Head to Head Analysis: Nektar Therapeutics (NKTR) and Its Competitors

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Nektar Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, profitability, risk, valuation, dividends and earnings.

Profitability

This table compares Nektar Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nektar Therapeutics -339.67% -29.31% -22.32%
Nektar Therapeutics Competitors -12,516.26% -215.91% -31.70%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Nektar Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics 1 4 10 1 2.69
Nektar Therapeutics Competitors 9920 15331 45733 1601 2.54

Nektar Therapeutics presently has a consensus target price of $130.33, indicating a potential upside of 278.66%. As a group, “Biotechnology” companies have a potential upside of 108.08%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Nektar Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nektar Therapeutics $52.19 million -$164.08 million -5.33
Nektar Therapeutics Competitors $750.79 million $11.26 million -18.46

Nektar Therapeutics’ peers have higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Nektar Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Nektar Therapeutics’ peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.

Summary

Nektar Therapeutics beats its peers on 9 of the 13 factors compared.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.